Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.54 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.54 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13508987 | 0.83 | ADORA3 (0.59) | ALDH1A1CA12CA9ADORA3ADORA2A | |
| SCHEMBL6980480 | 0.80 | CMA1 (0.57) | ALDH1A1CA12CA9ADORA3ADORA2A | |
| SCHEMBL7467460 | 0.75 | CMA1 (0.75) | ALDH1A1CA12CA9ADORA3ADORA2A | |
| SCHEMBL6982044 | 0.74 | CMA1 (0.48) | ALDH1A1CA12CA9ADORA3ADORA2A | |
| SCHEMBL3754362 | 0.74 | ALDH1A1 (1.00) | ALDH1A1CA12CA9ADORA3ADORA2A | |
| SCHEMBL14596922 | 0.72 | CA12 (0.66) | ALDH1A1CA12CA9KDM4ESMN1; SMN2 | |
| Carbazole SCHEMBL28081524 | 0.71 | ALDH1A1 (0.70) | ALDH1A1CA12CA9CYP1A2KDM4E | |
| SCHEMBL13947065 | 0.71 | ALDH1A1 (0.61) | ALDH1A1CA12CA9ADORA3ADORA2A | |
| SCHEMBL1520708 | 0.71 | FEN1 (1.00) | ALDH1A1CA12CA9ADORA3ADORA2A | |
| SCHEMBL19577287 | 0.71 | ALDH1A1 (0.61) | ALDH1A1CA12CA9ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | claimed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | claimed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | claimed |
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| CN-102906085-A | 2, 4-dioxo-1, 4-dihydro-2H-quinazolin-3-yl-sulfonamide derivatives | NOVARTIS AG | 2013-01-30 | — | — | CN | disclosed |
| CN-102906085-A | 2, 4-dioxo-1, 4-dihydro-2H-quinazolin-3-yl-sulfonamide derivatives | NOVARTIS AG | 2013-01-30 | — | — | CN | disclosed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | GRIK2, GRIK1, GRIK4 | ALDH1A1 387/4885CA12 1465/4885CA9 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.